|
This is an archived document. The links
and content are no longer being updated.
Table 7. Resistance to Isoniazid with or without Rifampin Resistance in Reported
TB Cases with No Previous TB by Origin: United States, 1993-2000
|
Year |
Resistant to Isoniazid¹ |
| Total Cases² |
U.S.-born |
Foreign-born³ |
| No. |
% |
No. |
% |
No. |
% |
| 1993 |
1,400 |
8.4 |
804 |
6.8 |
579 |
12.4 |
| 1994 |
1,355 |
8.3 |
709 |
6.4 |
632 |
12.1 |
| 1995 |
1,171 |
7.3 |
554 |
5.4 |
615 |
11.0 |
| 1996 |
1,138 |
7.4 |
496 |
5.2 |
639 |
11.3 |
| 1997 |
1,082 |
7.5 |
436 |
5.0 |
640 |
11.2 |
| 1998 |
1,012 |
7.5 |
366 |
4.7 |
644 |
11.3 |
| 1999 |
904 |
7.1 |
284 |
4.1 |
618 |
11.0 |
| 2000 |
851 |
7.5 |
261 |
4.4 |
587 |
11.0 |
- Isolates may be resistant to other drugs.
- Includes persons of unknown country of birth.
- Includes persons born outside the United States, American Samoa, the Federated
States of Micronesia, Guam, the Republic of the Marshall Islands, Midway Island,
the Commonwealth of the Northern Mariana Islands, Puerto Rico, the Republic
of Palau, U.S. Minor Outlying Islands, U.S. Miscellaneous Pacific Islands,
and the U.S. Virgin Islands.
Note: Data for all years updated through April 17, 2001.
More than 85% of all cases in each group had drug susceptibility test results
reported for an initial isolate.
See Surveillance
Slide #14.
| Year |
Resistant to Isoniazid and Rifampin¹ |
| Total Cases² |
U.S.-born |
Foreign-born³ |
| No. |
% |
No. |
% |
No. |
% |
| 1993 |
410 |
2.5 |
302 |
2.6 |
105 |
2.3 |
| 1994 |
352 |
2.2 |
238 |
2.2 |
109 |
2.1 |
| 1995 |
252 |
1.6 |
168 |
1.6 |
84 |
1.5 |
| 1996 |
206 |
1.3 |
104 |
1.1 |
101 |
1.8 |
| 1997 |
156 |
1.1 |
75 |
0.9 |
80 |
1.4 |
| 1998 |
130 |
1.0 |
55 |
0.7 |
74 |
1.3 |
| 1999 |
128 |
1.0 |
39 |
0.6 |
89 |
1.6 |
| 2000 |
120 |
1.1 |
38 |
0.6 |
82 |
1.5 |
- Isolates may be resistant to other drugs.
- Includes persons of unknown country of birth.
- Includes persons born outside the United States, American Samoa, the Federated
States of Micronesia, Guam, the Republic of the Marshall Islands, Midway Island,
the Commonwealth of the Northern Mariana Islands, Puerto Rico, the Republic
of Palau, U.S. Minor Outlying Islands, U.S. Miscellaneous Pacific Islands,
and the U.S. Virgin Islands.
Note: Data for all years updated through April 17, 2001.
More than 85% of all cases in each group had drug susceptibility test results
reported for an initial isolate.
See Surveillance
Slide #15.
Last Reviewed: 05/18/2008
Content Source: Division of Tuberculosis Elimination
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Back to Top of Page
|
You will need Adobe Acrobat™ Reader
v5.0 or higher to read pages that are in PDF format. Download the Adobe Acrobat™ Reader.
If you have difficulty accessing any
material on the DTBE Web site because of a disability, please contact
us in writing or via telephone and we will work with you to make the information
available.
Division of Tuberculosis Elimination
Attn: Content Manager, DTBE Web site
Centers for Disease Control and Prevention
1600 Clifton Rd., NE Mailstop E-10
Atlanta, GA 30333
CDC-INFO at (1-800) 232-4636
TTY: 1 (888) 232-6348
E-mail: tbinfo@cdc.gov
|
Home | Site Map
| Contact Us
Accessibility
| Privacy Policy Notice |
FOIA
| USA.gov
CDC Home |
Search |
Health Topics A-Z
Centers for Disease Control & Prevention
National Center for HIV/AIDS,
Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination
Please send comments/suggestions/requests to:
CDCINFO@cdc.gov
|
